| Literature DB >> 25687575 |
Onno A Spruijt1, Harm-Jan Bogaard, Martijn W Heijmans, Rutger J Lely, Mariëlle C van de Veerdonk, Frances S de Man, Nico Westerhof, Anton Vonk-Noordegraaf.
Abstract
The most common feature of pulmonary hypertension (PH) on computed tomography pulmonary angiography (CTPA) is an increased diameter-ratio of the pulmonary artery to the ascending aorta (PA/AAAX). The aim of this study was to investigate whether combining PA/AAAX measurements with ventricular measurements improves the predictive value of CTPA for precapillary PH. Three predicting models were analysed using baseline CTPA scans of 51 treatment naïve precapillary PH patients and 25 non-PH controls: model 1: PA/AAAX only; model 2: PA/AAAX combined with the ratio of the right ventricular and left ventricular diameter measured on the axial view (RV/LVAX); model 3: PA/AAAX combined with the RV/LV-ratio measured on a four chamber view (RV/LV4CH). Prediction models were compared using multivariable binary logistic regression, ROC analyses and decision curve analyses (DCA). Multivariable binary logistic regression showed an improvement of the predictive value of model 2 (-2LL = 26.48) and 3 (-2LL = 21.03) compared to model 1 (-2LL = 21.03). ROC analyses showed significantly higher AUCs of model 2 and 3 compared to model 1 (p = 0.011 and p = 0.007, respectively). DCA showed an increased clinical benefit of model 2 and 3 compared to model 1. The predictive value of model 2 and 3 were almost equal. We found an optimal cut-off value for the RV/LV-ratio for predicting precapillary PH of RV/LV ≥ 1.20. The predictive value of CTPA for precapillary PH improves when ventricular and pulmonary artery measurements are combined. A PA/AAAX ≥ 1 or a RV/LVAX ≥ 1.20 needs further diagnostic evaluation to rule out or confirm the diagnosis.Entities:
Mesh:
Year: 2015 PMID: 25687575 PMCID: PMC4428842 DOI: 10.1007/s10554-015-0618-x
Source DB: PubMed Journal: Int J Cardiovasc Imaging ISSN: 1569-5794 Impact factor: 2.357
Fig. 1CTPA parameters a Pulmonary artery (PA) and ascending aorta (AA) ratio (PA/AAAX) on an axial view at the level of the bifurcation of the pulmonary trunk. b Right ventricle (RV) and left ventricle (LV) ratio (RV/LVAX) on an axial view. The RV diameter is measured perpendicular to the long axis of the heart. The LV diameter is not measured in this image, since the maximum diameter of the LV is not necessarily on the same image c RV/LV4CH on a four chamber (4CH) view
Prediction models
| Prediction models | |
|---|---|
| Model 1 | PA/AAAX |
| Model 2 | PA/AAAX + RV/LVAX |
| Model 3 | PA/AAAX + RV/LV4CH |
PA/AA ratio between PA and AA, RV/LV ratio between RV and LV in the axial plane RV/LV ratio between RV and LV in the 4CH view
Baseline characteristics
| PH (N = 51) | Controls (N = 25) | |
|---|---|---|
| Gender | 71 % female | 76 % female |
| Age (years) | 56 ± 16 | 55 ± 15 |
| Precapillary PH | ||
| PAH | 41 | |
| CTEPH | 10 | |
| mPAP (mmHg) | 48 ± 16 | 16 ± 4* |
| PAWP (mmHg) | 7 ± 3 | 6 ± 3 |
| PVR (Dyne.s/cm5) | 774 ± 452 | 126 ± 70* |
| RAP (mmHg) | 8 ± 5 | 3 ± 2* |
| CO (L/min) | 5.1 ± 0.3 | 6.9 ± 0.4* |
IPAH idiopathic pulmonary arterial hypertension, CTEPH chronic trombo-embolic pulmonary hypertension, mPAP mean pulmonary artery pressure, PAWP pulmonary artery wedge pressure, PVR pulmonary vascular resistance, RAP right atrial pressure, CO cardiac output
* p < 0.05 compared with the PH group
CTPA parameters
| CTPA parameters | PH | Controls |
|---|---|---|
| PA/AAAX | 1.20 ± 0.30 | 0.85 ± 0.13* |
| RV/LVAX | 1.62 ± 0.42 | 1.00 ± 0.20* |
| RV/LV4CH | 1.65 ± 0.42 | 1.00 ± 0.18* |
Mean values ± SD
PA/AA ratio between PA and AA RV/LV ratio between RV and LV in the axial plane RV/LV ratio between RV and LV in the 4CH view
* p < 0.05 compared with the PH group
Univariable binary logistic regression analysis
| CTPA parameters | −2LL | B | OR | 95 % C.I. |
|
|---|---|---|---|---|---|
| PA/AAAX | 56.56 | 1.19 | 3.27 | 1.78–6.03 |
|
| RV/LVAX | 47.22 | 0.82 | 2.26 | 1.51–3.39 |
|
| RV/LV4CH | 44.77 | 0.86 | 2.37 | 1.51–3.71 |
|
B beta, OR odds ratio, 95 % C.I. 95 % confidence interval
Multivariate binary logistic regression analysis
| Prediction models | −2LL | B | OR | 95 % C.I. |
| |
|---|---|---|---|---|---|---|
| Model 1 | PA/AAAX | 56.56 | 1.19 | 3.27 | 1.78–6.03 |
|
| Model 2 | PA/AAAX | 26.48 | 1.79 | 5.99 | 1.67–21.45 |
|
| RV/LVAX | 0.82 | 2.28 | 1.37–3.78 |
| ||
| Model 3 | PA/AAAX | 21.03 | 2.40 | 10.98 | 1.73–69.52 |
|
| RV/LV4CH | 1.12 | 3.07 | 1.46–6.46 |
|
−2LL = log-likelihood statistic, B beta, OR odds ratio, 95 % C.I. 95 % confidence interval
Fig. 2Area Under the Curve (AUC) of the three different models. Blue line = model 1, Green line = model 2, Red line = model 3
Fig. 3Decision curve analysis. Decision curve analysis of the three models to predict the presence of precapillary PH. On the right an expended view of the curves at low threshold probabilities, ranging from 0 to 20 %
Net benefits(NB) of model 1, 2 and 3
| Threshold probability % | False Positives | NB PH all | NB Model 1: PA/AAAX | Delta NB | Decrease in false positives (per 100 patients) without an increase in false negatives |
|---|---|---|---|---|---|
| 1 | 25 | 0.6677299 | 0.6677299 | 0.0000000 | 0 |
| 2 | 24 | 0.6643394 | 0.6646079 | 0.0002685 | 1 |
| 5 | 22 | 0.6537396 | 0.6558172 | 0.0020776 | 4 |
| 10 | 19 | 0.6345029 | 0.6432749 | 0.0087720 | 8 |
| 15 | 18 | 0.6130031 | 0.6160991 | 0.0030960 | 2 |
| 20 | 18 | 0.5888158 | 0.5855263 | −0.0032895 | −1 |
| Threshold probability % | False Positives | NB PH all | NB Model 2: PA/AAAX + RV/LVAX | Delta NB | Decrease in false positives (per 100 patients) without an increase in false negatives |
| 1 | 18 | 0.6677299 | 0.6686603 | 0.0009304 | 9 |
| 2 | 17 | 0.6643394 | 0.6664877 | 0.0021482 | 11 |
| 5 | 13 | 0.6537396 | 0.6620499 | 0.0083102 | 16 |
| 10 | 10 | 0.6345029 | 0.6564328 | 0.0219298 | 20 |
| 15 | 9 | 0.6130031 | 0.6501548 | 0.0371517 | 21 |
| 20 | 7 | 0.5888158 | 0.6480263 | 0.0592105 | 24 |
| Threshold probability % | False Positives | NB PH all | NB Model 3: PA/AAAX + RV/LV4CH | Delta NB | Decrease in false positives (per 100 patients) without an increase in false negatives |
| 1 | 16 | 0.6677299 | 0.6689261 | 0.0011962 | 12 |
| 2 | 14 | 0.6643394 | 0.6672932 | 0.0029538 | 14 |
| 5 | 10 | 0.6537396 | 0.6641274 | 0.0103878 | 20 |
| 10 | 8 | 0.6345029 | 0.6593567 | 0.0248538 | 22 |
| 15 | 6 | 0.6130031 | 0.6571207 | 0.0441176 | 25 |
| 20 | 6 | 0.5888158 | 0.6513158 | 0.0625000 | 25 |
The net benefit (NB) is calculated as: NB = (true positives/n)−[(false positives/n) × (Pt/(1-Pt)]. Subsequently, the decrease in false positives per 100 patients without an increase in false negatives is calculated as: (NBmodel−NBall) × 100(Pt/1-Pt)
PT threshold probability [21, 22]
Sensitivity, specificity, positive predictive values and negative predictive values
| Prediction models | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|
|
| ||||
| PA/AAAX ≥ 1 | 75 | 92 | 95 | 64 |
|
| ||||
| PA/AAAX ≥ 1 or RV/LVAX ≥ 1 | 100 | 48 | 80 | 100 |
| PA/AAAX ≥ 1 or RV/LVAX ≥ 1.10 | 100 | 68 | 86 | 100 |
| PA/AAAX ≥ 1 or RV/LVAX ≥ 1.15 | 98 | 76 | 89 | 95 |
| PA/AAAX ≥ 1 or RV/LVAX ≥ 1.20 | 94 | 80 | 91 | 87 |
| PA/AAAX ≥ 1 or RV/LVAX ≥ 1.30 | 94 | 84 | 92 | 88 |
|
| ||||
| PA/AAAX ≥ 1 or RV/LV4CH ≥ 1 | 100 | 40 | 77 | 100 |
| PA/AAAX ≥ 1 or RV/LV4CH ≥ 1.10 | 100 | 68 | 86 | 100 |
| PA/AAAX ≥ 1 or RV/LV4CH ≥ 1.15 | 98 | 76 | 89 | 95 |
| PA/AAAX ≥ 1 or RV/LV4CH ≥ 1.20 | 96 | 80 | 91 | 91 |
| PA/AAAX ≥ 1 or RV/LV4CH ≥ 1.30 | 94 | 84 | 92 | 88 |
PPV positive predictive value, NPV negative predictive value